AOD-9604 vs hGH Fragment 176-191: What the Terms Mean

Are AOD-9604 and hGH Fragment 176-191 the Same?

In search behavior, "AOD-9604" and "hGH fragment 176-191" are often used interchangeably. For precise research writing, it is cleaner to separate the terms: hGH fragment 176-191 describes the C-terminal fragment concept from human growth hormone, while AOD-9604 refers to a modified synthetic peptide developed from that region.

FDA Pharmacy Compounding Advisory Committee materials characterize AOD-9604 as a 16-amino-acid peptide and review it as a historical obesity-development candidate, not as an approved routine medicine.^[3]

Term-by-Term Comparison

What the Rodent Studies Showed

Ng et al. studied AOD-9604 in obese Zucker rats and reported reduced weight gain with increased adipose-tissue lipolytic activity after 19 days of oral administration. The same paper reported that chronic AOD-9604 exposure did not worsen insulin sensitivity in that model under the measures used.^[1]

Heffernan et al. later reported reduced body weight and body fat in obese mice, together with changes in beta-3 adrenergic receptor RNA expression in adipose tissue. Their knockout-model findings suggested a more complex pathway than a simple direct beta-3 receptor agonist story.^[2]

Those studies justify research interest. They do not establish strong human efficacy, and they should not be repackaged as outcome promises.

What FDA PCAC Materials Add

The most useful modern summary comes from FDA's December 4, 2024 Pharmacy Compounding Advisory Committee briefing and presentation documents. Those materials state that a larger 24-week study in 536 enrolled adults did not show significant weight loss compared with placebo and that development for obesity was terminated in 2007.^[4]

The same FDA source set notes that the molecular target and mechanism remained insufficiently defined in the reviewed material. For a conservative research-use page, that means AOD-9604 should be framed as a compound with historical preclinical signal and clear evidence limits, not as a proven body-composition product.

How Remy Frames AOD-9604

For Remy Peptides, the compliant framing is narrow: AOD-9604 is a research compound supplied for in-vitro laboratory research only, with product-format details kept separate from the evidence review. See the main AOD-9604 research guide, the AOD-9604 10mg research vial, the storage guide, and the COA/HPLC guide.

How AOD-9604 Modifies the 176-191 Fragment

Building on that separation, it helps to be precise about the modification itself. The fragment label 176-191 names the C-terminal region of human growth hormone; AOD-9604 corresponds to that tail (residues 177-191) carrying an additional tyrosine residue at the N-terminal end, written in some primary literature as Tyr-hGH 177-191. That added tyrosine is the practical reason the modified peptide is given its own code name rather than simply being called the fragment.

This is why the two terms are searched almost interchangeably yet are not strictly identical. AOD-9604 is a defined, tyrosine-modified analog of the 176-191 region, consistent with the FDA PCAC characterization of AOD-9604 as a 16-amino-acid peptide rather than the intact hormone.^[3] For research writing, the useful precision is that the metabolic-pathway interest reported in the rodent literature attaches to this specific modified peptide,^[1] not to the fragment label as an abstract idea.

AOD-9604 vs Tesamorelin: A Different Mechanistic Class

A related search people run is aod 9604 vs tesamorelin, and the two should not be merged. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), a peptide on the secretion side of the growth hormone axis,^[5] rather than a peptide derived from the hormone molecule itself.

AOD-9604, by contrast, is built from the C-terminal tail of the growth hormone protein, the same region named by hGH fragment 176-191. In other words, tesamorelin sits upstream of growth hormone as a releasing-hormone analog, while AOD-9604 is a downstream fragment-derived analog of the hormone. Treating them as interchangeable would blur two genuinely different starting points in the same pathway.

For a conservative research-reference page, the takeaway is that comparisons between AOD-9604 and tesamorelin are comparisons across peptide classes, not within one. Study designs, reported mechanisms, and regulatory histories differ between a GHRH analog and a growth-hormone-fragment analog, so evidence about one does not transfer to the other.